Strengthening Rockville as a major player in global healthcare
We have 2000 scientists working from one of our three global vaccines R&D Centers to support our portfolio of more than 40 vaccines. One of those Centers is right here in Rockville.
More than a dozen of our vaccine/R&D development programs are based out of the Slaoui Center for Vaccines Research in Rockville.
This site, which opened in 2016, is the first US-based R&D site for our vaccines business, joining sites in Rixensart (Belgium) and Siena (Italy).
The team here are working to expand our efforts to discover and develop novel vaccines across a range of pressing public health threats. In addition, Rockville is home to our biopharmaceutical manufacturing team.
“Montgomery County — and Rockville in particular — is a great location for GSK due to its proximity to Washington, DC and our key US stakeholders.
This county is an established and growing bioscience center that offers us great opportunities now and for the future. It’s also an ideal location for collaborations with a host of well-regarded academic institutions. It is a center of emerging talent for our research workforce, with its proximity to the Universities at Shady Grove, University of Maryland at College Park, and other centers of bioscience education and training,” shared Christopher Maddox, Director of Site Operations for the Slaoui Center.
The facility is 650,000+ square feet and sits on nearly 50 acres of land. And – should anyone ask -- if every set of stairs within the facility were stacked on top of one another, they’d be as tall as the Washington Monument!
If you have time to take a look around, here's a peek inside Rockville.